Schrodinger sees FY25 software revenue growth up 10%-15%

Sees FY25: Software revenue growth is expected to range from 10% to 15%. Drug discovery revenue is expected to range from $45 million to $50 million. Software gross margin is expected to range from 74% to 75%. Operating expense growth in 2025 is expected to be less than 5%. Cash used for operating activities in 2025 is expected to be significantly lower than cash used for operating activities in 2024. Sees Q1 software revenue $44 million to $48 million.